Explain When Study Results Are Clinically Meaningful to Patients

November 2017

It can be hard to decide whether STATISTICALLY significant findings are CLINICALLY significant.

Consider the new COMPASS trial in patients with stable CV disease. It's stirring up controversy...and is a good example.

It suggests that adding Xarelto (rivaroxaban) 2.5 mg BID to low-dose aspirin reduces the risk of a CV event versus aspirin alone...with a p-value less than 0.001.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

12 issues every year, with brief articles about new meds and guidelines
48+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Cholesterol Improve Patient Adherence to Statins
Antiplatelets Feel Comfortable Switching Many Patients to Clopidogrel Early After a Stent
NSAIDs Continue to Limit Celecoxib and Other NSAIDs in High-CV-Risk Patients
Kidney Disease Help Chronic Kidney Disease Patients Manage Itching From Uremic Pruritus
Neurology & Pain Consider OTC Alternatives to Lidoderm
Interactions Tell Patients to Separate All Oral Meds From Potassium Binders
Gout Don't Jump to Combo Med Duzallo for Chronic Gout
Pregnancy Use Strategies to Minimize Opioids and Treat Opioid Use Disorder in Pregnancy
Practice Explain When Study Results Are Clinically Meaningful to Patients
Gastroenterology Don't Be Surprised if Patients Report They're Swallowing Inhaled Steroids
Antibiotics Don't Use Baxdela to Treat Most Skin Infections
Cardiology Watch for Dosing Differences With the New Spironolactone Suspension CaroSpir

Explain When Study Results Are Clinically Meaningful to Patients

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Table of Contents